Taken overall, these in vivo data demonstrate that KRASG12D expression is necessary for tumor formation, but insufficient to support progressive tumor growth, while combined expression with GATAD2B drives progressive tumor growth that is dependent on continued KRASG12D signaling. The gene discussed is GATAD2B; the disease is neoplasm.